Gilead to appeal India patent ruling on hepatitis C drug
January 16, 2015 at 05:42 AM EST
MUMBAI, Jan 16 (Reuters) - U.S.-based Gilead Sciences Inc will appeal the Indian patent office's rejection of its application for hepatitis C drug Sovaldi, a move that could allow local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.
